XML 60 R32.htm IDEA: XBRL DOCUMENT v3.22.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2022
Share-Based Payment Arrangement [Abstract]  
Schedule of Share-Based Compensation Expense
The following table summarizes the stock-based compensation expense recognized under all of the Company’s stock plans for the three and six months ended June 30, 2022 and 2021, and associated with the issuance of restricted shares of common stock and vesting of stock options, which are included in general and administrative expenses in the accompanying consolidated statements of income (in thousands):

Three Months Ended
June 30,		Six Months Ended
June 30,
2022202120222021
Stock options$1,141 $602 $1,921 $1,191 
Restricted stock2,779 954 5,054 1,711 
Total stock-based compensation expense$3,920 $1,556 $6,975 $2,902 
Schedule of Stock Option Transactions Under Stock Option Plans
The Company’s outstanding stock options consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Options outstanding at January 1, 2022813,965 $22.74 3.20$41.6 
Options granted
87,488 53.18 — — 
Options exercised
(38,500)17.37 — 0.9 
Options outstanding at June 30, 2022862,953 $26.07 2.69$16.3 
Options exercisable at June 30, 2022624,513 $11.04 1.70$14.9 
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions
During the six months ended June 30, 2022, the Company granted 87,488 stock options to certain ApolloMed employees and Board members. The options granted during the six months ended June 30, 2022 were recognized at fair value, as determined using the Black-Scholes option pricing model as follows:
June 30, 2022
Expected term
1.50 years - 2.25 years
Expected volatility
71.47% - 82.05%
Risk-free interest rate
1.02% - 2.47%
Market value of common stock
$17.47 - $22.73
Schedule of Outstanding Warrants
The Company’s outstanding warrants consisted of the following:
Shares
Weighted
Average
Exercise Price
Weighted
Average
Remaining
Contractual
Term
(Years)
Aggregate
Intrinsic
Value
(in millions)
Warrants outstanding at January 1, 20221,001,740 10.49 0.9463.1 
Warrants granted— — — — 
Warrants exercised(101,953)10.49 — 4.0 
Warrants expired/forfeited— — — — 
Warrants outstanding at June 30, 2022899,787 $10.49 0.44$25.3 

Exercise Price Per Share
Warrants
Outstanding
Weighted
Average
Remaining
Contractual Life
Warrants
Exercisable
Weighted
Average
Exercise Price
Per Share
$10.00 462,7430.44462,743 $10.00 
11.00 437,0440.44437,044 $11.00 
$ 10.00 – 11.00
899,787 0.44899,787 $10.49